Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001753926-25-001111
Filing Date
2025-07-08
Accepted
2025-07-08 16:05:35
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12335
2 EXHIBIT 1 g084878_ex1.htm EX-1 5792
  Complete submission text file 0001753926-25-001111.txt   19996
Mailing Address 140 BROADWAY 38TH FLOOR NEW YORK NY 10005
Business Address 874 WALKER ROAD SUITE C DOVER DE 19904 (646) 845-0040
3i, LP (Filed by) CIK: 0001841619 (see all company filings)

EIN.: 843800874 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902
Business Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902 9176446313
Pelthos Therapeutics Inc. (Subject) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94460 | Film No.: 251111098
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)